Envista

Envista (NYSE:NVST) this week posted second-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates.

The Brea, California-based dental technology company reported profits of $47.1 million, or 26¢ per share, on sales of $645.8 million for the three months ended July 1, for a bottom-line loss of 47.7% on sales growth of 1.35% compared with Q2 2021.

Adjusted to exclude one-time items, earnings per share were 48¢, 2¢ ahead of The Street, where analysts were looking for sales of $650.6 million.

“We delivered another solid quarter achieving core sales growth of 4% and adjusted EBITDA margins of 19.7%. Our team continues to utilize our EBS tools to successfully navigate a challenging operating environment marked by significant supply chain disruptions, accelerating inflation, geopolitical uncertainties, and a severe COVID-related lockdown in China. I am proud of how our team continues to build a track record of execution des…

Envista (NYSE:NVST) shares are on the rise on first-quarter results that came in ahead of the consensus forecast.

The Brea, California-based dental technology company posted profits of $74.9 million, or 42¢ per share, on sales of $631.4 million for the three months ended April 1, 2022, for a 4.5% bottom-line gain on sales growth of 3.1%.

Adjusted to exclude one-time items, earnings per share were 47¢, 4¢ ahead of Wall Street, where analysts were looking for sales of $628.4 million.

“In addition to delivering a solid first quarter, we continue to make progress in transforming our portfolio,” Envista CEO Amir Aghdaei said in a news release. “With the closing of the acquisition of Carestream Dental’s Intraoral Scanner (IOS) business, we have now added a suite of world-class scanners and software solutions that further differentiate our portfolio and support our vision of digitizing, personalizing, and democratizing dental care.

“Our…

Envista (NYSE:NVST) shares ticked up before hours today on fourth-quarter results that topped the consensus forecast.

The Brea, California-based dental technology company posted profits of $85.8 million, or 48¢ per share, on sales of $651.8 million for the three months ended Dec. 31, 2021, for a 20.8% bottom-line slide on sales growth of 5.8%.

Adjusted to exclude one-time items, earnings per share were 46¢, 4¢ ahead of Wall Street, where analysts were looking for sales of $634.7 million.

“We are pleased with our fourth-quarter results and remain optimistic about the future of the dental industry. Given our recent portfolio moves, we are now more focused on the faster-growing, most attractive segments of the dental industry,” Envista CEO Amir Aghdaei said in a news release. “Ultimately, we remain committed to our purpose of partnering with professionals to improve patients’ lives and will continue to work to personalize, digitize, and democrat…

Envista this week announced that it has entered into a binding agreement to sell its KaVo treatment unit and instrument business to Planmeca for up to $455 million.

Through the deal, Planmeca will pay up to $455 million with a potential earn-out payment of up to $30 million. The sale is expected to close at the end of this year.

The KaVo treatment unit and instruments is a manufacturer and supplier of dental treatment units and instruments. The business to be sold is part of Envista’s equipment and consumables segment. Envista’s imaging business will remain a part of the company as part of the equipment and consumables segment.

“Envista is focused on its strategic priorities to build and optimize a more consumables and digitally-enabled, workflow-oriented portfolio. This sale will better position Envista to invest organically and inorganically and expand our product offerings within these areas,” CEO Amir Aghdaei said in a news release.…

Envista (NYSE:NVST) today posted second-quarter results that beat the overall consensus on Wall Street.

The Brea, Calif.-based company reported profits of $90.1 million, or 51¢ per share, on sales of $740.1 million for the three months ended July 2, for a sales growth of 104.45% compared with Q2 2020.

Adjusted to exclude one-time items, earnings per share were 53¢, 8¢ ahead of The Street, where analysts were looking for sales of $707.8 million.

“We delivered another strong quarter driven by continued recovery in the dental market and solid execution across our portfolio. Core sales growth was 102% compared to a COVID-19 impacted second quarter of 2020. Our adjusted EBITDA margin was 19% for the current quarter. We also grew above pre-pandemic levels with core sales growth of 5.6% compared to the same quarter of 2019,” CEO Amir Aghdaei said in a news release.

“Our team has done a tremendous job of executing our business priorities in the quar…